CARM · Insider Trading
CARISMA THERAPEUTICS INC
Every open-market purchase and sale reported by CARM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-08 | Michael Klichinsky | Chief Scientific Officer | MIXED | — | −$8.22K |
| 2025-10-03 | Michael Klichinsky | Chief Scientific Officer | Sell | −484,347 | −$124.34K |
| 2025-01-30 | Steven Kelly | President and CEO | A | +500,000 deriv. | — |
| 2025-01-30 | Michael Klichinsky | Chief Scientific Officer | A | +221,000 deriv. | — |
| 2024-11-01 | Sohanya Roshan Cheng | Director | A | +38,700 deriv. | — |
| 2024-07-01 | Marella Thorell | Director | A | +38,700 deriv. | — |
| 2024-07-01 | David Scadden | Director | A | +38,700 deriv. | — |
| 2024-06-27 | John Hohneker | Director | A | +19,350 deriv. | — |
| 2024-06-27 | Michael Torok | Director | A | +19,350 deriv. | — |
| 2024-06-27 | Sanford S Zweifach | Director | A | +19,350 deriv. | — |
| 2024-06-27 | Briggs Morrison | Director | A | +19,350 deriv. | — |
| 2024-06-18 | Richard Steven Morris | Chief Financial Officer | A | +85,000 deriv. | — |
| 2024-06-18 | Michael Klichinsky | Chief Scientific Officer | A | +85,000 deriv. | — |
| 2024-06-18 | Steven Kelly | President and CEO | A | +125,000 deriv. | — |
| 2024-04-01 | John Hohneker | Director | A | +38,700 deriv. | — |
| 2024-02-02 | Steven Kelly | President and CEO | A | +438,000 deriv. | — |
| 2024-02-02 | Michael Klichinsky | Chief Scientific Officer | A | +170,500 deriv. | — |
| 2024-02-02 | Richard Steven Morris | Chief Financial Officer | A | +170,500 deriv. | — |
| 2023-06-08 | Briggs Morrison | Director | A | +38,700 deriv. | — |
| 2023-06-08 | Sanford S Zweifach | Director | A | +38,700 deriv. | — |
| 2023-06-08 | Richard Steven Morris | Chief Financial Officer | A | +238,000 deriv. | — |
| 2023-06-08 | Michael Torok | Director | A | +38,700 deriv. | — |
| 2023-06-08 | Michael Klichinsky | Chief Scientific Officer | A | +238,000 deriv. | — |
| 2023-06-08 | Chidozie Ugwumba | Director | A | +38,700 deriv. | — |
| 2023-06-08 | Steven Kelly | President and CEO | A | +600,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Klichinsky | Chief Scientific Officer | 56,982 | $6 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CARM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.